We recommend these technologies with approved Patient Access Schemes and other commercial arrangements, for use in the NHS.

Find out more about Patient Access Schemes

 
Guidance ref Treatment generic name Treatment brand name Indication Company Type 
HST2 Elosulfase alfa Vimizim Mucopolysaccharidosis type IVa BioMarin PAS (Simple Discount)
HST3 Ataluren Translarna Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene PTC Therapeutics PAS (Simple Discount)
HST4 Migalastat Galafold Fabry disease Amicus Therapeutics PAS (Simple Discount)
HST5 Eliglustat Cerdelga Type 1 Gaucher disease Sanofi PAS (Simple Discount)
TA129 Bortezomib Velcade Multiple myeloma Janssen PAS (Complex - Response scheme)
TA155 Ranibizumab Lucentis Macular degeneration (Acute wet AMD) Novartis PAS (Simple Discount)
TA169 Sunitinib Sutent Renal cell carcinoma Pfizer PAS (Complex - Free Stock)
TA171 Lenalidomide Revlimid Multiple myeloma Celgene PAS (Complex - Dose Cap)
TA179 Sunitinib Sutent Gastrointestinal stromal tumour Pfizer PAS (Complex - Free Stock)
TA185 Trabectedin Yondelis Advanced soft tissue sarcoma PharmaMar PAS (Complex - Dose Cap)
TA192 Gefitinib Iressa Non small cell lung cancer AstraZeneca PAS (Complex - Single Fixed Price)
TA215 Pazopanib Votrient Advanced renal cell carcinoma Novartis PAS (Complex Discount) 
TA218 Azacitidine Vidaza Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia Celgene PAS (Simple Discount)
TA220 Golimumab Simponi Psoriatic arthritis Merck Sharp & Dohme PAS (Complex - Free Stock)
TA221 Romiplostim Nplate Chronic idiopathic (immune) thrombocytopenic purpura Amgen PAS (Simple Discount)
TA225 Golimumab Simponi Rheumatoid arthritis Merck Sharp & Dohme PAS (Complex - Free Stock)
TA235 Mifamurtide Mepact High grade resectable non-metastatic osteosarcoma Takeda PAS (Simple Discount)
TA238 Tocilizumab RoActemra Systemic juvenile idiopathic arthritis Roche PAS (Simple Discount)
TA247 Tocilizumab RoActemra Rheumatoid arthritis Roche PAS (Simple Discount)
TA254 Fingolimod Gilenya Highly active relapsing-remitting multiple sclerosis Novartis PAS (Simple Discount)
TA258 Erlotinib Tarceva First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer Roche PAS (Simple Discount)
TA259 Abiraterone acetate Zytiga Castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen Janssen CAA (PAS withdrawn July 2016)
TA265 Denosumab Xgeva Skeletal related events in adults with bone metastases from solid tumours Amgen PAS (Simple Discount)
TA268 Ipilimumab Yervoy Advanced melanoma, 2nd Line Bristol-Myers Squibb PAS (Simple Discount)
TA269 Vemurafenib Zelboraf Metastatic mutation positive melanoma Roche PAS (Simple Discount)
TA274 Ranibizumab Lucentis Diabetic macular odema Novartis PAS (Simple Discount)
TA276 Tobramycin TOBI Podhaler Pseudomonas aeruginosa for adults and children over 6 with cystic fibrosis Novartis PAS (Simple Discount)
TA276 Colistimethate Colobreathe Pseudomonas aeruginosa for adults and children over 6 with cystic fibrosis Teva PAS (Simple Discount)
TA278 Omalizumab Xolair Severe persistant asthma Novartis PAS (Simple Discount)
TA283 Ranibizumab Lucentis Macular oedema secondary to retinal vein occlusion Novartis PAS (Simple Discount)
TA293 Eltrombopag Revolade Chronic immune (idiopathic) thrombocytopenic purpura Novartis PAS (Simple Discount)
TA294 Aflibercept Eylea Wet age‑related macular degeneration Bayer PAS (Simple Discount)
TA298 Ranibizumab Lucentis Choroidal neovascularisation secondary to pathologic myopia Novartis PAS (Simple Discount)
TA301 Fluocinolone Iluvien Diabetic macula oedema Alimera Sciences PAS (Simple Discount)
TA303 Teriflunomide Aubagio Active relapsing-remitting multiple sclerosis Sanofi PAS (Simple Discount)
TA305 Aflibercept Eylea Visual impairment caused by macular oedema secondary to central retinal vein occlusion Bayer PAS (Simple Discount)
TA306 Pixantrone Pixuvri Multiple relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma Servier Laboratories PAS (Simple Discount)
TA310 Afatinib Giotrif Locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Boehringer Ingelheim PAS (Simple Discount)
TA316 Enzalutamide Xtandi Metastatic hormone-relapsed prostate cancer in adults whose disease has progressed during or after docetaxel-containing chemotherapy Astellas PAS (Simple Discount)
TA319 Ipilimumab Yervoy Adults with previously untreated advanced (unresectable or metastatic) melanoma Bristol-Myers Squibb PAS (Simple Discount)
TA320 Dimethyl fumarate Tecfidera Adults with active relapsing‑remitting multiple sclerosis Biogen PAS (Simple Discount)
TA321 Dabrafenib Tafinlar Unresectable or metastatic melanoma with a BRAFV600 mutation Novartis PAS (Simple Discount)
TA322 Lenalidomide Revlimid Myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality Celgene PAS (Complex - Dose Cap)
TA329 Golimumab Simponi moderately to severely active ulcerative colitis Merck Sharp & Dohme PAS (Complex - Free Stock)
TA333 Axitinib Inlyta Advanced renal cell carcinoma after failure of prior systemic treatment Pfizer PAS (Simple Discount)
TA339 Omalizumab Xolair Previously treated chronic spontaneous urticaria Novartis PAS (Simple Discount)
TA342 Vedolizumab Entyvio Moderately to severely active ulcerative colitis Takeda PAS (Simple Discount)
TA343 Obinutuzumab Gazyvaro Untreated chronic lymphocytic leukaemia Roche PAS (Simple Discount)
TA344 Ofatumumab Arzerra Untreated chronic lymphocytic leukaemia Novartis PAS (Simple Discount)
TA346 Aflibercept Eylea Diabetic macular oedema Bayer PAS (Simple Discount)
TA347 Nintedanib Vargatef Previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer Boehringer Ingelheim PAS (Simple Discount)
TA350 Secukinumab Cosentyx Moderate to severe plaque psoriasis Novartis PAS (Simple Discount)
TA352 Vedolizumab Entyvio Moderately to severely active Crohn's disease after prior therapy Takeda PAS (Simple Discount)
TA357 Pembrolizumab Keytruda Advanced melanoma after disease progression with ipilimumab Merck Sharp & Dohme CAA (PAS withdrawn September 2017)
TA358 Tolvaptan Jinarc Autosomal dominant polycystic kidney disease Otsuka Pharmaceuticals PAS (Simple Discount)
TA359 Idelalisib Zydelig Chronic lymphocytic leukaemia Gilead Simple Discount Agreement (SDA) 
TA366 Pembrolizumab Keytruda Advanced melanoma not previously treated with ipilimumab Merck Sharp & Dohme CAA (PAS withdrawn September 2017)
TA373 Abatacept Orencia Polyarticular juvenile idiopathic arthritis Bristol-Myers Squibb PAS (Simple Discount)
TA373 Tocilizumab RoActemra Polyarticular juvenile idiopathic arthritis Roche PAS (Simple Discount)
TA374 Erlotinib Tarceva Non-small-cell lung cancer that has progressed after prior chemotherapy Roche PAS (Simple Discount)
TA375 Abatacept Orencia For rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed Bristol-Myers Squibb PAS (Simple Discount)
TA375 Golimumab Simponi For rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed Merck Sharp & Dohme PAS (Complex - Free Stock)
TA375 Tocilizumab RoActemra For rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed Roche PAS (Simple Discount)
TA375 Certolizumab pegol Cimzia For rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed UCB Pharma PAS (Complex - Free Stock)
TA377 Enzalutamide Xtandi Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Astellas PAS (Simple Discount)
TA379 Nintedanib Ofev Idiopathic pulmonary fibrosis Boehringer Ingelheim PAS (Simple Discount)
TA380 Panobinostat Farydak Multiple myeloma after at least 2 previous treatments Novartis PAS (Simple Discount)
TA381 Olaparib Lynparza Maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy AstraZeneca PAS (Complex - Time Cap)
TA383 Golimumab Simponi TNF-alpha inhibitors for ankylosing spondylitis. Merck Sharp & Dohme PAS (Complex - Free Stock)
TA383 Certolizumab pegol Cimzia TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis UCB Pharma PAS (Complex - Free Stock)
TA386 Ruxolitinib Jakavi Disease-related splenomegaly or symptoms in adults with myelofibrosis. Novartis PAS (Simple Discount)
TA387 Abiraterone acetate Zytiga Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Janssen CAA (PAS withdrawn July 2016)
TA391 Cabazitaxel Jevtana Hormone-relapsed metastatic prostate cancer treated with docetaxel. Sanofi PAS (Simple Discount)
TA392 Adalimumab Humira Moderate to severe hidradenitis suppurativa AbbVie PAS (Discounted Price - This Indication Only)
TA393 Alirocumab Praluent Primary hypercholesterolaemia and mixed dyslipidaemia Sanofi PAS (Simple Discount)
TA394 Evolocumab Repatha Primary hypercholesterolaemia and mixed dyslipidaemia Amgen PAS (Simple Discount)
TA395 Ceritinib Zykadia Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer Novartis PAS (Simple Discount)
TA396 Trametinib Mekinist In combination with dabrafenib for treating unresectable or metastatic melanoma Novartis PAS (Simple Discount)
TA396 Dabrafenib Tafinlar In combination with trametinib for treating unresectable or metastatic melanoma Novartis PAS (Simple Discount)
TA397 Belimumab Benlysta Active autoantibody-positive systemic lupus erythematosus GlaxoSmithKline PAS (Simple Discount)
TA401 Bosutinib Bosulif Previously treated chronic myeloid leukaemia Pfizer PAS (Simple Discount)
TA402 Pemextred Alimta Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin Eli Lilly Commercial Access Agreement (CAA) 
TA405 Trifluridine and tipiracil hydrochloride Lonsurf Previously treated metastatic colorectal cancer Servier Laboratories PAS (Simple Discount)
TA406 Crizotinib Xalkori Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer Pfizer PAS (Simple Discount)
TA407 Secukinumab Cosentyx Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors Novartis PAS (Simple Discount)
TA409 Aflibercept Eylea Visual impairment caused by macular oedema after branch retinal vein occlusion Bayer PAS (Simple Discount)
TA410 Talimogene laherparepvec Imlygic Unresectable metastatic melanoma Amgen PAS (Simple Discount)
TA412 Radium-223 dichloride Xofigo Hormone-relapsed prostate cancer with bone metastases Bayer PAS (Simple Discount)
TA415 Certolizumab pegol Cimzia Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor UCB Pharma PAS (Complex - Free Stock)
TA416 Osimertinib Tagrisso Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer AstraZeneca Commercial Access Agreement (CAA) 
TA417 Nivolumab Opdivo Previously treated advanced renal cell carcinoma in adults Bristol-Myers Squibb CAA (PAS withdrawn September 2017)
TA419 Apremilast Otezla Moderate to severe plaque psoriasis Celgene PAS (Simple Discount)
TA421 Everolimus Afinitor Advanced breast cancer after endocrine therapy Novartis PAS (Simple Discount)
TA422 Crizotinib Xalkori Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer Pfizer PAS (Simple Discount)
TA423 Eribulin Halaven Breast cancer (locally advanced, metastatic) Eisai PAS (Simple Discount)
TA424 Pertuzumab Perjeta Neoadjuvant treatment of breast cancer Roche PAS (Simple Discount)
TA425 Dasatinib Sprycel Imatinib-resistant or intolerant chronic myeloid leukaemia Bristol-Myers Squibb PAS (Simple Discount)
TA425 Nilotinib Tasigna Imatinib-resistant or intolerant chronic myeloid leukaemia Novartis PAS (Simple Discount)
TA426 Nilotinib Tasigna Untreated chronic myeloid leukaemia Novartis PAS (Simple Discount)
TA426 Dasatinib Sprycel Untreated chronic myeloid leukaemia Bristol-Myers Squibb PAS (Simple Discount)
TA427 Pomalidomide Imnovid Multiple myeloma previously treated with lenalidomide and bortezomib Celgene PAS (Simple Discount)
TA428 Pembrolizumab Keytruda PD-L1-positive non-small-cell lung cancer after chemotherapy Merck Sharp & Dohme CAA (PAS withdrawn September 2017)
TA429 Ibrutinib Imbruvica Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation Janssen PAS (Simple Discount)
TA430 Sofosbuvir-vepatasvir Epculsa Chronic hepatitis C Gilead Simple Discount Agreement (SDA) 
TA431 Mepolizumab Nucala Severe refractory eosinophilic asthma GlaxoSmithKline PAS (Simple Discount)
TA432 Everolimus Afinitor Renal cell carcinoma Novartis PAS (Simple Discount)
TA433 Apremilast Otezla Active psoriatic arthritis Celgene PAS (Simple Discount)
TA439 Panitumumab Vectibix Previously untreated metastatic colorectal cancer Amgen CAA (PAS withdrawn September 2017)
TA439 Cetuximab Erbitux Previously untreated metastatic colorectal cancer Merck PAS (Simple Discount)
TA442 Ixekizumab Taltz Moderate to severe plaque psoriasis Eli Lilly PAS (Simple Discount)
TA443 Obeticholic acid Ocaliva Primary biliary cholangitis Intercept Pharma PAS (Simple Discount)
TA445 secukinumab Cosentyx Active psoriatic arthritis after inadequate response to DMARDs Novartis PAS (Simple Discount)
TA445 Certolizumab pegol Cimzia Active psoriatic arthritis after inadequate response to DMARDs UCB Pharma PAS (Complex - Free Stock)
TA447 Pembrolizumab Keytruda Untreated PD-L1-positive metastatic non-small-cell lung cancer Merck Sharp & Dohme CAA (PAS withdrawn September 2017)
TA448 Etelcalcetide Parsabiv Secondary hyperparathyroidism Amgen PAS (Simple Discount)
TA449 Everolimus Afinitor Unresectable or metastatic neuroendocrine tumours in people with progressive disease Novartis PAS (Simple Discount)
TA450 Blinatumomab Blincyto Previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia Amgen PAS (Simple Discount)
TA451 Ponatinib Iclusig Chronic myeloid leukaemia and acute lymphoblastic leukaemia Incyte Corporation PAS (Simple Discount)
TA457 Carfilzomib Kyprolis Previously treated multiple myeloma Amgen PAS (Simple Discount)
TA458 Trastuzuamb emtansine Kadcyla Breast cancer Roche PAS (Simple Discount)
TA462 Nivolumab Opdivo Relapsed or refractory classical Hodgkin lymphoma Bristol-Myers Squibb CAA (PAS withdrawn September 2017)
TA463 Cabozantinib Cabometyx Previously treated advanced renal cell carcinoma Ipsen PAS (Simple Discount)
TA465 Olaratumab Lartruvo Advanced soft tissue sarcoma Eli Lilly Commercial Access Agreement (CAA) 
TA466 Baricitinib Olumiant Moderate to severe rheumatoid arthritis Eli Lilly PAS (Simple Discount)
TA467 Ex vivo expanded autologous human corneal epithelial cells containing stem cells Holoclar Limbal stem cell deficiency after eye burns Chiesi Farmaceutici PAS (Simple Discount)
TA472 Obinutuzumab Gazyvaro Rituximab refractory follicular lymphoma Roche PAS (Simple Discount)
TA473 Cetuximab Erbitux Recurrent or metastatic squamous cell cancer of the head and neck Merck CAA (PAS withdrawn August 2017)
TA474 Sorafenib Nexavar Advanced hepatocellular carcinoma Bayer Commercial Access Agreement (CAA) 
TA476 Nab-paclitaxel Abraxane Adenocarcinoma of the pancreas Celgene PAS (Simple Discount)
TA478 Brentuximab vedotin Adcetris Refractory systemic anaplastic large cell lymphoma Takeda PAS (Simple Discount)
TA479 Reslizumab Cinqaero Eosinophilic asthma Teva PAS (Simple Discount)
TA480 Tofacitinib Xeljanz Moderate to severe active rheumatoid arthritis Pfizer PAS (Simple Discount)
TA483 Nivolumab Opdivo Squamous non-small cell lung cancer (sqNSCLC) Bristol-Myers Squibb Commercial Access Agreement (CAA) 
TA484 Nivolumab Opdivo Locally advanced or metastatic non-squamous non-small-cell lung cancer  Bristol-Myers Squibb  Commercial Access Agreement (CAA) 
TA485 Sarilumab Kevzara Moderate to severe active rheumatoid arthritis Sanofi PAS (Simple Discount)
TA486 Aflibercept Eylea Myopic choroidal neovascularisation Bayer PAS (Simple Discount)
TA487 Venetoclax Venclyxto Chronic lymphocytic leukaemia (CLL)  AbbVie Commercial Access Agreement (CAA) 
TA488 Regorafenib Stivarga Previously treated gastrointestinal stromal tumours in adults  Bayer  PAS (Simple Discount)
TA490 Nivolumab Opdivo Recurrent or metastatic squamous-cell carcinoma of the head and neck  Bristol-Myers Squibb  Commercial Access Agreement (CAA) 
TA491 Ibrutinib Imbruvica Waldenstroms macro-globulinaemia (WM)  Janssen  Commercial Access Agreement (CAA) 
TA492 Atezolizumab Tecentriq Locally advance or metastatic urothelial carcinoma (MuC) after prior chemotherapy or who are considered cisplatin ineligible  Roche  PAS (Simple Discount)
TA495 Palbociclib Ibrance Hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) negative  Pfizer  PAS (Simple Discount)
TA496 Ribociclib Kisqali Breast Cancer Novartis PAS (Simple Discount)
TA497 Golimumab Simponi Non-radiographic axial spondyloarthritis Merck Sharp & Dohme PAS (Complex - Free Stock)
TA498 Lenvatinib Kisplyx Renal cell carcinoma (RCC)  Eisai  PAS (Simple Discount)
TA500 Ceritinib Zykadia Anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)  Novartis  PAS (Simple Discount)
TA502 Ibrutinib Imbruvica For treating relapsed or refractory mantle cell lymphoma  Janssen  Commercial Access Agreement (CAA) 
TA504 Pirfenidone Esbriet Moderate idiopathic pulmonary fibrosis Roche PAS (Simple Discount)
TA505 Ixazomib Ninlaro Relapsed or refractory multiple myeloma Takeda Commercial Access Agreement (CAA) 
TA509 Pertuzumab Perjeta HER2-positive breast cancer Roche Commercial Access Agreement (CAA) 
TA510 Daratumumab Darzalex Relapsed and refractory multiple myeloma Janssen Commercial Access Agreement (CAA) 
TA511 Brodalumab Kyntheum Moderate to severe plaque psoriasis Leo Pharma PAS (Simple Discount)
TA512 Tivozanib Fotivda Advanced renal cell carcinoma EUSA Pharma PAS (Simple Discount)
TA513 Obinutuzunab Gazyvaro Untreated advanced follicular lymphoma Roche PAS (Simple Discount)
TA516 Cabozantinib Cometriq Medullary thyroid cancer Ipsen PAS (Simple Discount)
TA517 Avelumab Bavencio Metastatic Merkel cell carcinoma Merck Commercial Access Agreement (CAA) 
TA518 Tocilizumab RoActemra Giant cell arteritis Roche PAS (Simple Discount)
TA519 Pembrolizumab Keytruda Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy Merck Sharp & Dohme Commercial Access Agreement (CAA) 
TA520 Atezolizumab Tecentriq Locally advanced or metastatic non-small-cell lung cancer after chemotherapy  Roche  PAS (Simple Discount)
TA521 Guselkumab Tremfya Moderate to severe plaque psoriasis Janssen PAS (Simple Discount)
TA522 Pembrolizumab Keytruda Untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable Merck Sharp & Dohme Commercial Access Agreement (CAA) 
TA523 Midostaurin Rydapt Untreated acute myeloid leukaemia Novartis PAS (Simple Discount)
TA524 Brentuximab vedotin Adcetris CD30-positive Hodgkin lymphoma Takeda PAS (Simple Discount)
TA525 Atezolizumab Tecentriq Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy Roche PAS (Simple Discount)